Amgen buys cancer drugmaker for $10.4B

08/26/2013 | Reuters

Amgen agreed to acquire Onyx Pharmaceuticals for $125 per share, or around $10.4 billion, in the fifth-largest biotechnology deal ever. The agreement will give Amgen rights to several cancer drugs, including the multiple myeloma drug Kyprolis, liver and kidney cancer treatment Nexavar, and colon cancer drug Stivarga. The acquisition is expected to be finalized this year.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Chicago, IL
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC